{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:41Z","timestamp":1787026661254,"version":"build-2736575974"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We report vaccine and booster-related uveitis in Singapore, a country with high vaccination and booster rates to highlight the differences and potential role of prophylactic treatment for sight-threatening infectious uveitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data extracted from the de-identified uveitis database in Singapore National Eye Center. Six patients (eight eyes) developed uveitis within 14 days after undergoing COVID-19 vaccination (primary and\/or booster).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All patients received two doses of COVID-19 vaccination, and 1.39% (6\/431) developed COVID-19 vaccine-related uveitis. Fifty-percent% (3\/6) with non-infectious anterior uveitis (NIAU) presented with a non-granulomatous anterior uveitis (AU). The remaining (3\/6) presenting with a granulomatous AU were diagnosed with reactivation of cytomegalovirus, varicella-zoster virus and toxoplasma chorioretinitis, respectively. All the patients responded to definitive treatment specific to their diagnosis. The mean visual acuity at presentation was 0.36 \u00b1 0.20 logMAR and improved to 0.75 \u00b1 0.09 (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.009). Mean time from vaccination to uveitis was 9.7 (range: 3\u201314) days. All patients developed uveitis after second vaccination dose. 16.67% (1\/6) patients had a recurrence after the third booster dose. None of the three patients with infectious uveitis developed recurrence but had received maintenance therapy up to or during the booster.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Uveitis after COVID-19 vaccination is uncommon. In our series, a higher rate of reactivations of latent infections was seen. With definitive treatment, all cases were self-limited without systemic sequelae. Prophylactic treatment during booster vaccine may prevent reactivation of sight-threatening infections and reduce morbidity although risk-benefits should be considered for individual patients given the low rate of occurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2022.925683","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T01:16:15Z","timestamp":1655860575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center"],"prefix":"10.3389","volume":"9","author":[{"given":"Milton C.","family":"Chew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaan","family":"Wiryasaputra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Boon","family":"Khor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita S. Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.medj.2021.06.006","article-title":"Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines","volume":"2","author":"McMurry","year":"2021","journal-title":"Medicine."},{"key":"B2","first-page":"48","article-title":"Vaccine-associated uveitis","volume":"113","author":"Benage","year":"2016","journal-title":"Mo Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/09273948.2019.1626188","article-title":"Vaccine-associated uveitis","volume":"27","author":"Cunningham","year":"2019","journal-title":"Ocul Immunol Inflamm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.4103\/ijo.IJO_816_20","article-title":"Drug-induced uveitis: a review","volume":"68","author":"Agarwal","year":"2020","journal-title":"Indian J Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/ICU.0000000000000530","article-title":"Drug-induced uveitis","volume":"29","author":"Moorthy","year":"2018","journal-title":"Curr Opin Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1097\/IAE.0000000000003277","article-title":"Uveitis after the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association","volume":"41","author":"Rabinovitch","year":"2021","journal-title":"Retina."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12348-021-00275-x","article-title":"Ocular inflammatory events following COVID-19 vaccination: a multinational case series","volume":"12","author":"Testi","year":"2022","journal-title":"J Ophthalmic Inflam Infect."},{"key":"B8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/vaccines10020342","article-title":"Ocular complications following vaccination for COVID-19: a one-year retrospective","volume":"10","author":"Haseeb","year":"2022","journal-title":"Vaccines."},{"key":"B9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijid.2021.09.075","article-title":"Bilateral uveitis after inoculation with COVID-19 vaccine: a case report","volume":"113","author":"Pan","year":"2021","journal-title":"Int J Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/09273948.2021.1957123","article-title":"Bilateral multifocal choroiditis following COVID-19 vaccination","volume":"29","author":"Goyal","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamaophthalmol.2021.3477","article-title":"Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi","volume":"139","author":"Pichi","year":"2021","journal-title":"J Am Med Assoc Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.18502\/jovr.v16i3.9443","article-title":"COVID-19 recombinant mRNA vaccines and serious ocular inflammatory side effects: real or coincidence?","volume":"16","author":"Maleki","year":"2021","journal-title":"J Ophthalmic Vis Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijid.2021.07.035","article-title":"Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence?","volume":"110","author":"Renisi","year":"2021","journal-title":"Int J Infect Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/09273948.2021.1946567","article-title":"Acute macular neuroretinopathy following coronavirus disease 2019 vaccination","volume":"29","author":"Mambretti","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/09273948.2021.1949478","article-title":"Panuveitis following vaccination for COVID-19","volume":"29","author":"Mudie","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med."},{"key":"B18","unstructured":"Population in Brief"},{"key":"B19","unstructured":"COVID-19 Vaccination"},{"key":"B20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.autrev.2017.10.010","article-title":"Uveitis: diagnostic work-up. A literature review and recommendations from an expert committee","volume":"16","author":"S\u00e8ve","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"111199","DOI":"10.1016\/j.forsciint.2022.111199","article-title":"Post COVID-19 vaccine deaths - Singapore's early experience","volume":"332","author":"Yeo","year":"2022","journal-title":"Forensic Sci Int."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.12.03004","article-title":"The guiding principles for populational COVID-19 vaccine selection: a normative analysis through comparison of the strategies in Hong Kong and Singapore","author":"Chan","year":"","journal-title":"J Glob Health."},{"key":"B24","unstructured":""},{"key":"B25","doi-asserted-by":"publisher","first-page":"221490","DOI":"10.1136\/annrheumdis-2021-221490","article-title":"Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry","volume":"2021","author":"Machado","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B26","unstructured":"LiverTox: Clinical Research Information on Drug-Induced Liver Injury2012"},{"key":"B27","unstructured":"The Use of the WHO-UMC System for Standardised Case Causality Assessment"},{"key":"B28","doi-asserted-by":"publisher","first-page":"567395","DOI":"10.3389\/fpubh.2020.567395","article-title":"Clinical characteristics and diagnostic challenges of COVID\u221219: an update from the global perspective","volume":"8","author":"Israfil","year":"2020","journal-title":"Front Public Health."},{"key":"B29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/1756-185X.14238","article-title":"COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells","volume":"25","author":"Sachinidis","year":"2022","journal-title":"Int J Rheum Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2020.1853177","article-title":"Epidemiology of viral induced anterior uveitis","volume":"2021","author":"Radosavljevic","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3390\/vaccines9091013","article-title":"Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports","volume":"9","author":"Katsikas Triantafyllidis","year":"2021","journal-title":"Vaccines."},{"key":"B32","doi-asserted-by":"publisher","first-page":"S190","DOI":"10.4103\/injr.injr_137_21","article-title":"Herpes zoster reactivation after COVID-19 vaccination in patients with autoimmune diseases","volume":"60","author":"Sanjay","year":"","journal-title":"Indian J Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2022.2055580","article-title":"Herpes simplex virus 1 anterior uveitis following coronavirus disease 2019 (COVID-19) vaccination in an Asian Indian Female","volume":"2022","author":"Sangoram","year":"2022","journal-title":"Ocul Immunol Inflamm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"11206721211046484","DOI":"10.1177\/11206721211046485","article-title":"Reactivation of varicella zoster infection presenting as acute retinal necrosis post COVID 19 vaccination in an Asian Indian male","volume":"2021","author":"Mishra","year":"2021","journal-title":"Eur J Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"SI90","DOI":"10.1093\/rheumatology\/keab345","article-title":"Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series","volume":"60","author":"Furer","year":"2021","journal-title":"Rheumatology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"108665","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases?","volume":"224","author":"Talotta","year":"2021"},{"key":"B39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev-immunol-092419-031130","article-title":"Age-associated B cells","volume":"38","author":"Cancro","year":"2020","journal-title":"Annu Rev Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3389\/fimmu.2019.00318","article-title":"B cell dysfunction associated with aging and autoimmune diseases","volume":"10","author":"Ma","year":"2019","journal-title":"Front Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/vaccines10020193","article-title":"Comparing SARS-CoV-2 antibody responses after various COVID-19 vaccinations in healthcare workers","volume":"10","author":"Kim","year":"2022","journal-title":"Vaccines."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.vaccine.2022.01.002","article-title":"Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: an observational study of 646 Japanese healthcare workers and university staff","volume":"40","author":"Uwamino","year":"2022","journal-title":"Vaccine."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2022.2048559","article-title":"The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study","volume":"2022","author":"Jubishi","year":"2022","journal-title":"Hum Vaccin Immunother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3390\/vaccines9090977","article-title":"Occurrence of BNT162b2 vaccine adverse reactions is associated with enhanced SARS-CoV-2 IgG antibody response","volume":"9","author":"Rechavi","year":"2021","journal-title":"Vaccines."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.vaccine.2022.02.045","article-title":"Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2","volume":"40","author":"Kageyama","year":"2022","journal-title":"Vaccine."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","article-title":"Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine","volume":"597","author":"Oberhardt","year":"2021","journal-title":"Nature."},{"key":"B48","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.medj.2021.04.003","article-title":"Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset","volume":"2","author":"Kalimuddin","year":"2021","journal-title":"Medicine."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.4049\/jimmunol.182.2.1069","article-title":"Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication","volume":"182","author":"Gigley","year":"2009","journal-title":"J Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/mi.2017.102","article-title":"T-bet-independent Th1 response induces intestinal immunopathology during Toxoplasma gondii infection","volume":"11","author":"L\u00f3pez-Yglesias","year":"2018","journal-title":"Mucosal Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ajo.2019.12.025","article-title":"Long-term results of trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrent Toxoplasma gondii Retinochoroiditis","volume":"213","author":"Fernandes Felix","year":"2020","journal-title":"Am J Ophthalmol."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2022-321091","article-title":"Current practice in the management of ocular toxoplasmosis","author":"Yogeswaran","year":"2022","journal-title":"Br J Ophthalmol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2147\/OPTH.S60394","article-title":"Current aspects on the management of viral uveitis in immunocompetent individuals","volume":"9","author":"Pleyer","year":"2015","journal-title":"Clin Ophthalmol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.antiviral.2017.01.011","article-title":"Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"140","author":"Seo","year":"2017","journal-title":"Antiviral Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.925683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T09:39:36Z","timestamp":1656063576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.925683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":54,"alternative-id":["10.3389\/fmed.2022.925683"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.925683","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"article-number":"925683"}}